Reading APUS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track APUS free→Reading APUS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track APUS free→QuarterlyIQ Insights · APUS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), the board of directors of the Company (the “ Board ”) appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date. There are no arrangements or understandings between S…
Entry into a Material Definitive Agreement. On April 24, 2026, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), MindWave Innovations Inc, a Delaware corporation and a wholly owned subsidiary of the Company (“ MindWave ”), and Lokahi Therapeutics, Inc., a Nevada corporation (“ Lokahi ” and, together with the Company and MindWave, the “ Company Parties ”), together with Erik Emerson (“ Emerson ”), individually and in his capacity as Bio Business Representative under t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, on December 30, 2025 and March 20, 2026, certain stockholders of the Company, including the Inscobee Parties, purported to execute written consents of stockholders (the “ Stockholder Consents ”) to, among other things, remove Elona Kogan, Jakap Koo, Carol O’Donnell, and Dr. Bennett Weintraub from the Company’s board of dire…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On April 17, 2026, Apimeds Pharmaceuticals US, Inc. (the “ Company ”) received a notice from the NYSE Regulation staff of the New York Stock Exchange (“ NYSE ”) indicating that the Company is not in compliance with NYSE’s continued listing requirements under the timely filing criteria outlined in Section 1007 of the NYSE American Listed Company Manual as a result of the Company’s failure to t…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Original Report, on March 20, 2026, Inscobee Inc. (“ Inscobee ”) and Apimeds, Inc. (“ Apimeds Korea ”), provided the Company with an action by written consent of the majority stockholders of the Company (the “ Stockholder Consent ”), which, among other things, purported to remove Elona Kogan, Jakap Koo, Carol O’Donnel…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 20, 2026, Inscobee Inc. (KS:006490) (“ Inscobee ”) and Apimeds, Inc. (“ Apimeds Korea ”) sent a document claiming to be an action by written consent of the stockholders (the “ Stockholder Consent ”) to Apimeds Pharmaceuticals US, Inc. (the “ Company ”) which, among other things, claimed to remove all members of the board of directors of th…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 20, 2026, Apimeds, Inc. (“Apimeds Korea”) and Inscobee Inc. (“Inscobee”) together with other stockholders of Apimeds Pharmaceuticals US, Inc. (the “Company”) who beneficially own at least 66 2/3% of the voting power of the Company (the “Majority Stockholders”) delivered an action by written consent of the stockholders to the Company (the “…
Other Events. Business Expansion On March 20, 2026, the Board approved the expansion of the Company’s business into new business initiatives and operations, including pursuing strategic opportunities such as joint ventures with other Korean companies to expand the current business of the Company into Korean cosmetics, photo booth platform business and e-commerce markets (the “Business Expansion”). In connection therewith, the Boad approved the Company’s entry into non-binding memoranda of und…
Completion of Acquisition or Disposition of Assets. The disclosure set forth under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 30, 2025, the stockholders of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the “ Company ”), acting by written consent, removed Erik Emerson from the Company’s board of directors, effective as of such date. The removal was effected by the affirmative vote of stockholders holding a majority of the outstanding shares of commo…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 5, 2025, Dr. Vin Menon, a Director of Apimeds Pharmaceuticals US, Inc. (the “ Company ”), and Amir A. Dossal, an Independent Director of the Company, resigned from their positions on the Company’s Board of Directors. The resignations were not the result of any disagreement with the Company on any matter relating to the Company’s operati…
Entry Into a Material Definitive Agreement. Merger Agreement As previously disclosed, on December 1, 2025, Apimeds Pharmaceuticals US, Inc, a Delaware corporation (the “ Acquiror ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with (i) Apimeds Merger Sub, Inc., a Delaware corporation, (ii) MindWave Innovations Inc, a Delaware corporation (the “ Company ”), (iii) Lokahi Therapeutics, Inc., a Nevada corporation, and (iv) Erik Emerson, solely in his capacity as repres…
Material Modification to Rights of Security Holders. The information set forth in
Changes in Control of Registrant. The disclosure set forth above in
Entry Into A Material Definitive Agreement. Merger Agreement This section describes the material provisions of the Merger Agreement (as defined herein) but does not purport to describe all of the terms thereof. Apimeds Pharmaceuticals US, Inc.’s stockholders and other interested parties are urged to read such agreement in its entirety. The following summary is qualified in its entirety by reference to the complete text of the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1…
by reference. There are no family relationships between Dr. Menon, Amir Dossal, or any of the Acquiror’s officers and directors. Biographical information for Dr. Menon and Amir Dossal is set forth below: Dr. Vin Menon is a veteran in the technology services industry, who can be credited with the strategic direction behind several disruptive technology companies. In the corporate world, he has held various leadership positions at multinational corporations like HP & Compaq with global responsi…
Completion of Acquisition or Disposition of Assets. The disclosure set forth above in
by reference. The issuance of the Merger Consideration and the offer, sale and issuance of the Notes have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act. On December 1, 2025, the Acquiror issued a warrant to E.F. Hutton & Co. LLC, to purchase 712,880 shares of Acquiror Common Stock, at an exercise price of per share (the “ E.F. Hutton Warrant ”). The E…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The disclosure set forth above in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 13, 2025 (the “Effective Date”), Apimeds Pharmaceuticals US, Inc. (the “Company”) entered into an amendment (the “Amendment”) to the Executive Employment Agreement, dated September 21, 2023 (the “Agreement”), with Erik Emerson, the Company’s Chief Executive Officer (the “Executive”). Effective as of the Effective Date, the Amendment inc…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Erick J. Frim as Chief Financial Officer On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao. Mr. Frim, age 67 , has over 40 years’ experience in financial management and operations, having served most rece…
Entry into a Material Definitive Agreement. On May 16, 2025, Apimeds Pharmaceuticals US, Inc. (the “Company”) amended the terms of three outstanding promissory notes as further described below. On May 20, 2024, the Company issued to Inscobee Inc. (“Inscobee”) a promissory note in the principal amount of $100,000 (the “May 2024 Note”). On August 19, 2024, the Company issued to Inscobee a promissory note in the principal amount of $150,000 (the “August 2024 Note”). On March 31, 2025, the Compan…
Entry into a Material Definitive Agreement. On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (the “Company”) consummated its initial public offering (the “IPO”) of 3,375,000 shares of common stock, par value $0.01 per share (“Common Stock”), at a price of $4.00 per share, generating gross proceeds to the Company of $13.5 million before deducting underwriting discounts and offering expenses. The Company’s Registration Statement on Form S-1 (File No. 333-282324) for the IPO (the “Registration…
Unregistered Sales of Equity Securities. In connection with the closing of the IPO, three convertible promissory notes (as amended, the “Notes”) automatically converted into shares of Common Stock. Pursuant to the terms of the Notes, all outstanding accrued and unpaid interest owed under the Notes was to convert into Common Stock simultaneously with the consummation of an offering of Common Stock resulting in the listing of the Common Stock on the NYSE American, or other national securities e…
Importance-ranked changes since the prior daily snapshot.
Total stock risk rose by 13.2 points (from 9.2 to 22.4).
Market risk rose by 13.2 points (from 9.2 to 22.4).
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.